Omnicell (NASDAQ:OMCL) Given a $55.00 Price Target by Piper Sandler Analysts

Omnicell (NASDAQ:OMCL) received a $55.00 target price from equities research analysts at Piper Sandler in a research report issued on Monday, Marketbeat reports. The brokerage presently has an “overweight” rating on the stock. Piper Sandler’s price target would indicate a potential upside of 73.56% from the company’s current price.

Several other equities research analysts also recently commented on OMCL. Bank of America boosted their target price on shares of Omnicell from $30.00 to $34.00 and gave the stock a “neutral” rating in a research report on Friday, May 23rd. Wall Street Zen cut shares of Omnicell from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 9th. Benchmark cut their price target on shares of Omnicell from $62.00 to $40.00 and set a “buy” rating on the stock in a report on Wednesday, May 7th. Finally, Wells Fargo & Company boosted their price target on shares of Omnicell from $37.00 to $40.00 and gave the stock an “overweight” rating in a report on Monday, July 21st. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $46.71.

Omnicell Stock Performance

Shares of Omnicell stock opened at $31.69 on Monday. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.42 and a quick ratio of 1.24. The firm has a market cap of $1.46 billion, a P/E ratio of 63.38, a P/E/G ratio of 9.18 and a beta of 0.78. The firm has a 50 day simple moving average of $29.45 and a 200 day simple moving average of $32.34. Omnicell has a fifty-two week low of $22.66 and a fifty-two week high of $55.74.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Thursday, July 31st. The company reported $0.45 EPS for the quarter, beating analysts’ consensus estimates of $0.30 by $0.15. The business had revenue of $290.56 million for the quarter, compared to analyst estimates of $275.57 million. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. Omnicell’s quarterly revenue was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.51 EPS. Sell-side analysts predict that Omnicell will post 1.09 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Summit Investment Advisors Inc. lifted its position in shares of Omnicell by 6.9% in the 4th quarter. Summit Investment Advisors Inc. now owns 4,774 shares of the company’s stock worth $213,000 after acquiring an additional 307 shares during the period. GAMMA Investing LLC lifted its holdings in Omnicell by 37.1% during the second quarter. GAMMA Investing LLC now owns 1,694 shares of the company’s stock worth $50,000 after acquiring an additional 458 shares in the last quarter. Diversified Trust Co lifted its holdings in shares of Omnicell by 2.3% in the first quarter. Diversified Trust Co now owns 22,660 shares of the company’s stock valued at $792,000 after purchasing an additional 513 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in Omnicell by 7.4% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,040 shares of the company’s stock worth $236,000 after acquiring an additional 552 shares in the last quarter. Finally, Bridge City Capital LLC increased its position in Omnicell by 1.6% during the first quarter. Bridge City Capital LLC now owns 40,136 shares of the company’s stock worth $1,403,000 after buying an additional 650 shares during the last quarter. 97.70% of the stock is currently owned by institutional investors.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.